Starpharma ROCE
Qual é o ROCE de Starpharma?
O ROCE de Starpharma Holdings Limited é 0.00%
Qual é a definição de ROCE?
O retorno sobre o capital empregado (ROCE) é um índice financeiro que mede a lucratividade de uma empresa e a eficiência com que seu capital é usado.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de empresas na Setor Health Care em ASX em comparação com Starpharma
O que Starpharma faz?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Empresas com roce semelhantes a Starpharma
- Omega Alpha Spac tem ROCE de -0.01%
- The Gap tem ROCE de -0.01%
- Elemental Royalties Ltd tem ROCE de -0.01%
- Auburn National Bancorp tem ROCE de -0.01%
- Galaxy Digital tem ROCE de -0.01%
- The Gap tem ROCE de -0.01%
- Starpharma tem ROCE de 0.00%
- Tejon Ranch Co tem ROCE de 0.01%
- Glen Burnie Bancorp tem ROCE de 0.02%
- MSP Steel & Power tem ROCE de 0.02%
- TTL Beteiligungs- und Grundbesitz-AG tem ROCE de 0.03%
- First Foundation Inc tem ROCE de 0.03%
- FirstMark Horizon Acquisition tem ROCE de 0.03%